PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Irbesartan / Hydrochlorothiazide - Hypertension

PAD Profile : Irbesartan / Hydrochlorothiazide - Hypertension

Brand Names Include :
Co-Aprovel

Traffic Light Status

Status 1 of 1.

Status :
Green (see narrative)
Important
Formulations :
  • Not Specified
Important Information :
MHRA alert: Hydrochlorothiazide risk of non-melanoma skin cancer
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
Comments :
No comments returned.
Documents :

Guidelines

The following guidelines are available for this indication.

Other Drugs

Other Indications

Additional Documents

Committee Recommendations

Date
Committee Name
Narrative
03 May 2017
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
Irbesartan / hydrochlorothiazide is considered GREEN

Associated BNF Codes

02. Cardiovascular System
02.05.05. Renin-angiotensin system drugs
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More